NCI-2020-07076

A Phase 1 Study of SRF388 in Patients with Advanced Solid Tumors

Antibodies are part of our body's defense system. They can specifically recognize damaging substances in the body, including tumor cells. The drug SFR338 is a new immune therapy drug that works with the body’s immune system, turning it on and fighting tumors from growing. This clinical trial will study the effects and benefits of the drug SRF388, when given by itself or combined with other types of medicine, in patients with solid tumors like hepatocellular carcinoma (liver cancer).

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04374877

NCI-2020-07076

Clinical Trial Site: Sinai

To see all available clinical trials click here.